Brian M. Barth,Mark Kester,James H. Adair,Todd E. Fox
申请号：
US14997242
公开号：
US20160206633A1
申请日:
2016.01.15
申请国别(地区):
US
年份:
2016
代理人:
摘要：
Use of dhS1P and/or PhotoImmunoNanoTherapy as a therapeutic agent is described. Administration of therapeutically effective amounts of dhS1P decrease the number of Myeloid Derived Suppressor Cells and immune suppression in cancer patients. Administration of therapeutically effective amounts of dhS1P can be used as an adjuvant to conventional cancer therapies including immunotherapies. Therapeutic results can be achieved by directly administering dhS1P and/or by indirectly increasing the amount of dhS1P at the tumor site. The therapy permits the patients immune system to recognize and eliminate cancer cells reducing tumor size and extending patient survival.
